Combined-modality therapy for rectal cancer using irinotecan.

Abstract

Preoperative or postoperative pelvic radiation plus concurrent fluorouracil-based chemotherapy is standard adjuvant treatment for patients with T3 and/or N1/2 rectal cancer. Newer chemotherapeutic regimens have been developed for the treatment of patients with metastatic disease. Irinotecan (CPT-11, Camptosar)-based regimens have improved survival in patients with metastatic disease and are being actively investigated in combination with pelvic radiation therapy for patients with rectal cancer.

• Authors: Bruce D Minsky
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 16 Issue 5 Suppl 5 Pg. 35-8 (May 2002) ISSN: 0890-9091 [Print] United States
• PMID: 12109805 (Publication Type: Journal Article, Review)

Chemical References

• Irinotecan
• Fluorouracil
• Camptothecin

Topics

• Adenocarcinoma (drug therapy, pathology, radiotherapy)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Camptothecin (administration & dosage, analogs & derivatives)
• Clinical Trials as Topic
• Combined Modality Therapy
• Fluorouracil (administration & dosage)
• Humans
• Irinotecan
• Preoperative Care
• Radiotherapy, Adjuvant
• Rectal Neoplasms (drug therapy, pathology, radiotherapy)
• Treatment Outcome